Sartorius Stedim BiotechSDMHF +2.46%80 ROA % is 4.33% as of Mar. 2026, which is 67% below its 10-year median of 12.99. GuruFocus rates SDMHF with a GF Score™ of 80/100 and a GF Value™ of $239.66 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 63.13% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sartorius Stedim Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was $407 Mil.
Sartorius Stedim Biotech's average Total Assets over the quarter that ended in Mar. 2026 was $9,408 Mil. Therefore, Sartorius Stedim Biotech's annualized ROA % for the quarter that ended in Mar. 2026 was 4.33%.
The historical rank and industry rank for Sartorius Stedim Biotech's ROA % or its related term are showing as below:
SDMHF'
s ROA % Range Over the Past 10 Years
Min: 2.19 Med: 12.99 Max: 19.43
Current: 3.3
During the past 13 years, Sartorius Stedim Biotech's highest ROA % was 19.43%. The lowest was 2.19%. And the median was 12.99%.
SDMHF's ROA % is ranked better than 63.13% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs SDMHF: 3.30
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's ROA % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Sartorius Stedim Biotech (SDMHF) has a ROA % of 4.33% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sartorius Stedim Biotech and its competitors. This is 67% below median its historical median of 12.99. Over the past decade, Sartorius Stedim Biotech's ROA % has ranged from 2.19 to 19.43. According to the industry distribution chart, Sartorius Stedim Biotech ranks #316 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 36.9%.
Is Sartorius Stedim Biotech's ROA % too high?
Sartorius Stedim Biotech's current ROA % of 4.33% is 67% below median its 10-year median of 12.99. Over the past 10 years, this metric has ranged from a low of 2.19 to a high of 19.43. The Medical Devices & Instruments industry median ROA % is 0.59. Sartorius Stedim Biotech's value of 4.33% is 633.9% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #316 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #316 out of 857 companies for ROA %. This puts Sartorius Stedim Biotech in the upper half of its industry. The industry median ROA % is 0.59. Sartorius Stedim Biotech's value of 4.33% is 633.9% above this benchmark. Historically, Sartorius Stedim Biotech's own ROA % has ranged from 2.19 to 19.43 over the past decade. While the company's 10-year median is 12.99 vs. the industry median of 0.59, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current ROA % of 4.33% is 633.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current ROA % is 4.33%, which is 67% below median its own 10-year median of 12.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SDMHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $239.66, compared to a current price of $190.88 — trading 20.4% below its estimated fair value. The current ROA % is 4.33%, which is 67% below median its 10-year median of 12.99 and 633.9% above the Medical Devices & Instruments industry median of 0.59. Sartorius Stedim Biotech's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sartorius Stedim Biotech (SDMHF), the current ROA % is 4.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SDMHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $190.88 is trading 20.4% below its estimated GF Value™ of $239.66.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SDMHF:
ROA %: 4.33% (67% below median its 10-year median of 12.99)
GF Value™: $239.66 vs. price of $190.88 (20.4% below fair value)
Industry Position: 633.9% above the Medical Devices & Instruments median (#316 of 857)
No single metric tells the full story. See the SDMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
80GF Score
Get the complete analysis for SDMHF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDMHF has been successfully added to your 
